B
Bright Minds Biosciences
Biotechnology company creating the next generation of psychedelics to treat mental health and other CNS disorders
About Bright Minds Biosciences
Bright Minds Bio is a biotechnology company focused on developing next-generation therapeutics aimed at improving the lives of patients suffering from severe and life-altering brain diseases. The company leverages its extensive experience in the biology of the serotonergic system to create highly targeted drugs that address specific patient populations unmet by current treatments.
Bright Minds Bio operates in the pharmaceutical and biotechnology market, primarily serving patients with conditions such as pain, seizures, and neuropsychiatric disorders. The company's business model revolves around drug discovery and development, where it creates new chemical entities (NCEs) and modifies existing molecules to enhance therapeutic properties while minimizing side effects.
Revenue is generated through the development and commercialization of these specialized drugs, often in partnership with larger pharmaceutical companies or through direct sales. The company also benefits from intellectual property rights and potential milestone payments and royalties from licensing agreements.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2017
- Headquarters
- New York City, United States
- Listing
- IPO 2021
- Employees
- 11
- Open positions
- None listed
- Dealroom signal
- 53.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Mental Health, Spinout, Tech for Biotech and Pharma, Biotech and Pharma, Psychedelic Drugs, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITY✓Other financing | May 2026 | $0 | — | B Group | ↗ |
| POST IPO EQUITY✓Other financing | Jan 2026 | $100M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Bright Minds Biosciences is 4K monthly website visits, down 9.1% over the last three months. Bright Minds Biosciences's team grew 22.2% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
B Group
Other known investors3 additional known investors
University of Illinois Urbana Champaign
Explorer Equity Group
Vine Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bright Minds Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bright Minds Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.